/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES
OR DISSEMINATION IN THE UNITED
STATES/
TORONTO, Sept. 20,
2023 /CNW/ - DRI Healthcare Trust (TSX: DHT.UN)
(TSX: DHT.U) (the "Trust"), a global leader in providing financing
to advance innovation in the life sciences industry, announces the
closing of its previously announced bought deal public offering of
units, including the exercise in full of the underwriters'
over-allotment option, for a total of 9,430,000 units sold at a
price of C$11.00 per unit for gross
proceeds of C$104 million.
"We are pleased to announce the successful completion of our
latest financing," said Behzad
Khosrowshahi, the Trust's Chief Executive Officer. "This
milestone reflects not only the confidence our investors have in
our vision, but also the hard work and dedication of our entire
team. With this new capital infusion, we are well-positioned to
accelerate our growth and continue to generate accretive returns
for our unitholders. We are grateful for the support of our
existing and new investors, and excited about the opportunities
that lie ahead."
The offering was led by Scotiabank, CIBC Capital Markets and RBC
Capital Markets, and included a syndicate of underwriters including
National Bank Financial Inc., Canaccord Genuity Corp., Raymond
James Ltd., BofA Securities, UBS Securities Canada Inc. and
Stifel.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities, nor shall there be
any sale of the securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such jurisdiction.
The securities offered have not been registered under the United
States Securities Act of 1933, as amended, and may not be offered
or sold in the United States
absent registration or an applicable exemption from the
registration requirements.
About DRI Healthcare Trust
DRI Healthcare Trust is managed by DRI Capital Inc. ("DRI
Capital"), the pioneer in global pharmaceutical royalty
monetization with a more than 30-year history
of accelerating innovation by providing capital
to inventors, academic institutions and biopharma
companies. Since our founding in 1989, DRI Capital has deployed
more than US$2.5 billion, acquiring
more than 70 royalties on 40-plus drugs, including Eylea, Keytruda,
Orserdu, Spinraza, Stelara, Vonjo, Zejula, and Zytiga. DRI
Healthcare Trust's units are listed and trade on the Toronto Stock
Exchange in Canadian dollars under the symbol "DHT.UN"
and in U.S. dollars under the symbol "DHT.U". To learn more, visit
drihealthcare.com or follow us on LinkedIn. Copies of the
applicable offering documents may be obtained free of charge under
the Trust's profile on SEDAR+ at sedarplus.com.
SOURCE DRI Healthcare Trust
